<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0410538" disease_type="Disease or Syndrome" abbrv="PSACH">Pseudoachondroplasia</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PSACH</z:e>) and <z:hpo ids='HP_0002654'>multiple epiphyseal dysplasia</z:hpo> (MED) are relatively common <z:hpo ids='HP_0002652'>skeletal dysplasias</z:hpo> resulting in <z:hpo ids='HP_0008873'>short-limbed dwarfism</z:hpo>, <z:hpo ids='HP_0002829'>joint pain</z:hpo>, and stiffness </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PSACH</z:e> and the largest proportion of <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> MED (AD-MED) results from mutations in cartilage oligomeric matrix protein (COMP); however, AD-MED is genetically heterogenous and can also result from mutations in matrilin-3 (MATN3) and type IX collagen (COL9A1, COL9A2, and COL9A3) </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, <z:hpo ids='HP_0000007'>autosomal recessive</z:hpo> MED (rMED) appears to result exclusively from mutations in <z:chebi fb="100" ids="16189">sulphate</z:chebi> transporter solute carrier family 26 (SLC26A2) </plain></SENT>
<SENT sid="3" pm="."><plain>The diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PSACH</z:e> and MED can be difficult for the nonexpert due to various complications and similarities with other related diseases and often mutation analysis is requested to either confirm or exclude the diagnosis </plain></SENT>
<SENT sid="4" pm="."><plain>Since 2003, the European <z:hpo ids='HP_0002652'>Skeletal Dysplasia</z:hpo> Network (ESDN) has used an on-line review system to efficiently diagnose cases referred to the network prior to mutation analysis </plain></SENT>
<SENT sid="5" pm="."><plain>In this study, we present the molecular findings in 130 patients referred to ESDN, which includes the identification of novel and recurrent mutations in over 100 patients </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, this study provides the first indication of the relative contribution of each gene and confirms that they account for the majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PSACH</z:e> and MED </plain></SENT>
</text></document>